5-methyl-2-(1-methylimidazol-2-yl)-6-(1-propan-2-ylpyrazol-3-yl)-N-pyrimidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine
C21H22N10 — CID 169238054
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-methyl-2-(1-methylimidazol-2-yl)-6-(1-propan-2-ylpyrazol-3-yl)-N-pyrimidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine
5-methyl-2-(1-methylimidazol-2-yl)-6-(1-propan-2-ylpyrazol-3-yl)-N-pyrimidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine (PubChem CID 169238054) has the molecular formula C21H22N10 and a molecular weight of 414.48 g/mol. Its IUPAC name is 5-methyl-2-(1-methylimidazol-2-yl)-6-(1-propan-2-ylpyrazol-3-yl)-N-pyrimidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine.
Molecular Properties
| Compound Name | 5-methyl-2-(1-methylimidazol-2-yl)-6-(1-propan-2-ylpyrazol-3-yl)-N-pyrimidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine |
|---|---|
| PubChem CID | 169238054 |
| Molecular Formula | C21H22N10 |
| Molecular Weight | 414.48 g/mol |
| Exact Mass | 414.20 |
| IUPAC Name | 5-methyl-2-(1-methylimidazol-2-yl)-6-(1-propan-2-ylpyrazol-3-yl)-N-pyrimidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine |
| SMILES | Cc1c(-c2ccn(C(C)C)n2)cn2nc(-c3nccn3C)nc(Nc3ccncn3)c12 |
| InChI | InChI=1S/C21H22N10/c1-13(2)30-9-6-16(27-30)15-11-31-18(14(15)3)19(25-17-5-7-22-12-24-17)26-20(28-31)21-23-8-10-29(21)4/h5-13H,1-4H3,(H,22,24,25,26,28) |
| InChIKey | CWUKICKMTBAAPQ-UHFFFAOYSA-N |
| XLogP | 3.42 |
| TPSA | 103.64 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 10 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 414.48 |
| LogP ≤ 5 | 3.42 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 10 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 169238054 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.